Meglithan

Metformin Hydrochloride and Linagliptin, the active ingredient in Meglithan, is a biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving insulin sensitivity and enhancing glucose‑dependent insulin secretion. It is indicated for patients who require combined therapy to achieve glycemic targets.

GNH USA supplies Meglithan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Meglithan is used in the management of type 2 diabetes mellitus, either as monotherapy or in combination with other antidiabetic agents. - Type 2 diabetes mellitus (monotherapy): improves glycemic control when used with diet and exercise. - Type 2 diabetes mellitus (combination therapy): provides additional HbA1c reduction when added to other oral antidiabetic drugs or insulin. - Adjunct to lifestyle modification: helps achieve target fasting glucose levels when combined with diet and exercise.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Upper respiratory tract infection: nasopharyngitis or sore throat. - Metallic taste: transient alteration in taste perception. - Fatigue: general feeling of tiredness. - Mild hypoglycemia: especially when combined with insulin or sulfonylureas.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic complication. - Severe hypoglycemia: marked low blood glucose requiring assistance. - Pancreatitis: acute inflammation of the pancreas. - Anaphylactic reaction: severe allergic response with rash, swelling, or difficulty breathing. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Renal impairment worsening: decline in kidney function associated with metformin accumulation.

Before initiating therapy, evaluate patient-specific factors and monitor regularly. - Renal function: assess eGFR and avoid use in severe renal impairment. - Hepatic impairment: use with caution and monitor liver enzymes. - Risk of lactic acidosis: discontinue metformin if patient develops conditions predisposing to hypoxia. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Drug interactions: review concomitant medications for agents that may affect glucose control or renal clearance. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Meglithan may interact with several medicines that affect glucose metabolism or renal clearance. Major Interactions (Avoid): - Iodinated contrast agents in patients with reduced renal function: may precipitate acute kidney injury. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase linagliptin exposure. - Insulin or sulfonylureas: may cause severe hypoglycemia. Moderate Interactions (Monitor Closely): - Cimetidine: may modestly raise linagliptin plasma levels. - Diuretics (e.g., furosemide): can affect metformin elimination. - Alcohol consumption: increases risk of lactic acidosis, especially with metformin.